» Articles » PMID: 15987480

Early Rheumatoid Arthritis is Characterized by a Distinct and Transient Synovial Fluid Cytokine Profile of T Cell and Stromal Cell Origin

Overview
Publisher Biomed Central
Specialty Rheumatology
Date 2005 Jul 1
PMID 15987480
Citations 191
Authors
Affiliations
Soon will be listed here.
Abstract

Pathological processes involved in the initiation of rheumatoid synovitis remain unclear. We undertook the present study to identify immune and stromal processes that are present soon after the clinical onset of rheumatoid arthritis (RA) by assessing a panel of T cell, macrophage, and stromal cell related cytokines and chemokines in the synovial fluid of patients with early synovitis. Synovial fluid was aspirated from inflamed joints of patients with inflammatory arthritis of duration 3 months or less, whose outcomes were subsequently determined by follow up. For comparison, synovial fluid was aspirated from patients with acute crystal arthritis, established RA and osteoarthritis. Rheumatoid factor activity was blocked in the synovial fluid samples, and a panel of 23 cytokines and chemokines measured using a multiplex based system. Patients with early inflammatory arthritis who subsequently developed RA had a distinct but transient synovial fluid cytokine profile. The levels of a range of T cell, macrophage and stromal cell related cytokines (e.g. IL-2, IL-4, IL-13, IL-17, IL-15, basic fibroblast growth factor and epidermal growth factor) were significantly elevated in these patients within 3 months after symptom onset, as compared with early arthritis patients who did not develop RA. In addition, this profile was no longer present in established RA. In contrast, patients with non-rheumatoid persistent synovitis exhibited elevated levels of interferon-gamma at initiation. Early synovitis destined to develop into RA is thus characterized by a distinct and transient synovial fluid cytokine profile. The cytokines present in the early rheumatoid lesion suggest that this response is likely to influence the microenvironment required for persistent RA.

Citing Articles

Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: Baseline results of SAIL-RA.

McDermott G, Gill R, Byrne S, Gagne S, Wang X, Paudel M medRxiv. 2025; .

PMID: 39974108 PMC: 11838938. DOI: 10.1101/2025.01.24.25321091.


Metabolic reprogramming and macrophage expansion define ACPA-negative rheumatoid arthritis: insights from single-cell RNA sequencing.

Jiang Y, Hu Z, Huang R, Ho K, Wang P, Kang J Front Immunol. 2025; 15():1512483.

PMID: 39830504 PMC: 11739280. DOI: 10.3389/fimmu.2024.1512483.


The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib.

Tanaka Y, Atsumi T, Aletaha D, Schulze-Koops H, Fukada H, Watson C Rheumatol Ther. 2024; 12(1):53-66.

PMID: 39592547 PMC: 11751281. DOI: 10.1007/s40744-024-00725-7.


Antigen-specific T-cell frequency and phenotype mirrors disease activity in DRB1*04:04+ rheumatoid arthritis patients.

Rims C, Uchtenhagen H, Brooks K, Ng B, Posso S, Carlin J Clin Exp Immunol. 2024; 219(1).

PMID: 39492692 PMC: 11754868. DOI: 10.1093/cei/uxae102.


Circulating Baseline CXCR3Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis.

Scheffler J, Drevinge C, Lindholm C, Gjertsson I, Lend K, Hetland M ACR Open Rheumatol. 2024; 7(1):e11742.

PMID: 39411912 PMC: 11667770. DOI: 10.1002/acr2.11742.


References
1.
Buckley C, Amft N, Bradfield P, Pilling D, Ross E, Amara A . Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol. 2000; 165(6):3423-9. DOI: 10.4049/jimmunol.165.6.3423. View

2.
Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J . Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002; 46(4):894-8. DOI: 10.1002/art.10135. View

3.
Bathon J, Martin R, Fleischmann R, Tesser J, Schiff M, Keystone E . A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343(22):1586-93. DOI: 10.1056/NEJM200011303432201. View

4.
Joosten L, Lubberts E, Helsen M, Saxne T, Heinegard D, van den Berg W . Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res. 2000; 1(1):81-91. PMC: 17779. DOI: 10.1186/ar14. View

5.
Pap T, Muller-Ladner U, Gay R, Gay S . Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000; 2(5):361-7. PMC: 130137. DOI: 10.1186/ar113. View